Postgraduate Pathology Education at MSK: History and Prospects

This issue of the MSK Pathology Review includes an article on the history of pathology at MSK, written by Hapie Cristol and Marc Rosenblum, who filled with interesting details about the giants of pathology who preceded us. The training of pathology fellows has also been a critical part of the history of our department for more than 70 years, and all of the fellowship groups dating back to 1948 are captured in the photographs hanging in the Cytology corridor in our department. Our educational philosophy - to immerse the fellows in oncologic pathology material, with them taking the primary role in handling and reporting the cases, has been consistent throughout our history, but there have been significant changes in the training program over the past few decades including the addition of numerous subspecialty fellowship positions.

When I came to MSK in 1991, the structure of the oncologic surgical pathology fellowship had not been unchanged for decades. This fellowship was our only substantial training experience at that time, and my addition at the last minute increased the number of fellows from 11 to 12. The fellows’ rotations were simple: 10 months of surgical pathology, 1 month of autopsy, and 1 month for vacation. On the surgical pathology rotation, teams of three fellows would gross on the first day, read their slides on the second day, and sign out with the attendings on day three. Then repeat ad nauseam. Fellows were not actively involved in frozen sections, and departmental consult cases were dropped by the clinicians (who at that time came to the department to review these slides with us) into a large red box that sat on the enormous, slate, communal sign-out table in the middle of the busy work room. These cases were designated “red box” cases and were reviewed ad hoc by the sign out teams who were already engaged in reviewing biopsies and surgical cases. The atmosphere was chaotic but oddly relaxed, and clinicians filtered in and out, accessioners screamed “FROZEN SECTION” when a case was ready for the frozen team to engage, and fellows sat studiously at the side of the attendings, adjusting their written reports based on more learned feedback. Prior to the arrival of Juan Rosai, sign out was conducted using single headed microscopes; if a fellow was uncertain why an attending had modified her diagnosis, she was free to retain the slides to study them privately after sign out was completed. This first major change in this routine came when Dr. Rosai arrived, as he was determined to introduce dedicated rotations for frozen sections, his personal consults, and elective project (and double-headed microscopes!). To accomplish this, we modified the three-day rotation to a two-day system, in which the fellow would return to grossing following the morning sign out. The gross room at that time measured about 8-feet square, and standard procedures were standardized throughout the department. For the grossing assignment, fellows would gross cases at low tables and placing their tissue sections into reusable metal cassettes, along with a scrap of paper on which the case number and cassette designation were scrawled. The task of grossing specimens was not viewed as highly educational by prospective applicants to our fellowship, and we realized that maintaining our conviction that the gross evaluation provides essential diagnostic information (I still firmly believe this) was causing us to lose candidates before they ever visited our department. Thus, grossing is now largely going the way of electron microscopy and argyrophil stainings (with apologies to Lars Grimmelius, who is still alive and Emeritus Professor at Uppsala University), at least from the perspective of fellowship training. But luckily the excellent work of our PAs means that we still derive all the diagnostically critical information from gross evaluations. The second major evolution in our program has been the proliferation of many additional specialty fellowship positions. Originally developed as selected second year research-focused fellowships, the surgical pathology subspecialty fellowships now encompass nearly every diagnostic discipline, and the clinical work has extended to involve these fellows as well. Additionally, training programs in molecular genetic pathology, cytology, hemopathology, and experimental pathology have all expanded, to the point that our current group of 40 fellows includes more subspecialty fellows (23) than oncologic pathology fellows.

So what is in store for the future of postgraduate pathology education at MSK? It is becoming increasingly clear that our traditional model, where essentially all clinical cases pass through the hands of a fellow, may not be sustainable as the institutional volume continues to expand. It is true that training in pathology requires exposure to a critical volume of case material, but it is equally true that there are many novel diagnostic tools at hand, and contemporary training requires that time be reserved to expose fellows to all aspects of diagnostic pathology. Increasingly, prospective fellows are looking for subspecialty training rather than broad surgical pathology exposure, and combinations of subspecialty fellowships with molecular diagnostics or research fellowships are becoming more attractive. In order for us to grow with these changes, we must continually reevaluate our programs. The schedule we have today is enormously complex, but flexibility in training is a persistent request from our fellows. In order to become more creative with the fellowship program, Kay Park (Director of Education), Melissa Murray (Fellowship Training Program Director), and Nora Katabi (Associate Fellowship Training Program Director) are working with our departmental administration to look for more efficient ways to handle the clinical material, with the idea that adding ancillary assistance in the process could alleviate the need for fellows (and attendings) to devote so much time to operational details. This would free us to consider more creative structuring of the training program. The addition of pathology residents is also under discussion, to give us the chance to influence young pathologists at an even earlier stage in their development, as well as to offer teaching opportunities to the fellows and hopefully groom some physician-scientists to spend time in our research labs. All of these modifications will require considerable work and creativity, but I think we must attend to them to keep current with the needs of pathology trainees and ensure that MSK Pathology maintains its decades-long role in educating the very best practicing and academic anatomic pathologists. Creative suggestions are more than welcome.

- David Klimstra, MD
Redefining GYNECOLOGIC SARCOMAS

Sarah Chiang, MD, is making important contributions to GYN pathology, especially in uterine cancer.

By Hope Cristol

For a pathologist who sees herself primarily as a clinician, Sarah Chiang, MD, takes on some surprisingly challenging research projects. One of her latest: exploring the molecular abnormalities that underpin uterine sarcomas.

“There is incredible morphologic overlap among various uterine sarcomas,” says Dr. Chiang, who signs out gynecologic and urologic pathology cases at MSK. “Morphology unfortunately doesn’t cut it anymore, and we need molecular genetics to help us refine tumor classification and improve clinical management.”

Genetic abnormalities, particularly fusions resulting from gene rearrangements, are found in a variety of uterine mesenchymal tumor types, including endometrial stromal sarcomas. While historically, gene fusions have not been associated with distinctive morphologic features, recent discoveries including those made by Dr. Chiang identify high-grade sarcomas with unique genotypes and phenotypes.

“Molecular diagnostics has dramatically changed patient care in all areas, but particularly in hematopathology as well as bone and soft tissue pathology,” Dr. Chiang says. “I want to bring that on board as part of the routine diagnostic evaluation of gynecologic lesions, particularly, uterine sarcomas. Even at MSK, we sometimes have difficulty diagnosing unusual lesions. We need novel diagnostic biomarkers and therapeutic targets for these women with rare sarcomas.”

Her recent work includes identification of novel types of high-grade endometrial stromal sarcomas harboring ZC3H7B-BCOR fusions and BCOR internal tandem duplications as well as NTRK fusion-positive uterine spindle cell sarcomas resembling fibrosarcoma.

In addition to her research on fusion discovery, she is also developing a methylation-based uterine sarcoma classifier that may assist in the diagnosis of tumors that are difficult to classify or predict behavior.

“All of this would not be possible without the unique collaborative environment we have at MSK,” says Dr. Chiang. “Through collaborations with Drs. Cristina Antonescu, Marc Ladanyi, Robert Soslow and Britta Weigelt, we are able to make great discoveries in the realm of uterine sarcomas.”

SMART PURSUIT

GYN pathology is evolving. “It’s been, historically, morphology-based diagnoses. That is going to change significantly as molecular diagnostics becomes incorporated in disease classification and management,” Dr. Chiang says.

She plans to be part of the change, putting her early training to good use so that more women with rare tumors can get answers and, hopefully, better treatments.

Dr. Chiang completed her residency in Anatomic Pathology and the Robert E. Scully fellowship in gynecologic, obstetric, and urologic pathology at the Massachusetts General Hospital in 2012. Surprisingly, exposure to molecular diagnostics was very limited. “Our residency molecular rotation was only three weeks long out of the entire three years of anatomic pathology training,” Dr. Chiang says.

She felt it was insufficient for an aspect of pathology that crosses all subspecialties. So, she took a two-month elective in molecular pathology “to gain more experience and time at the bench performing and interpreting the various assays in the clinical lab.”

Nearly five years into her career as an attending at MSK, Dr. Chiang says, “I incorporate much of that knowledge into what I do today on both clinical and research fronts.”

3 HIGHLIGHTS FROM USCAP

In case you missed Dr. Chiang’s presentations at the 2018 U.S. and Canadian Academy of Pathology (USCAP) conference in Vancouver, these are some of the highlights:

1 Platform Presentation: A Newly Defined Entity of High-Grade Endometrial Stromal Sarcomas
- ZC3H7B-BCOR fusion was confirmed in 17 tumors, including some previously diagnosed as myxoid leiomyosarcoma and undifferentiated uterine sarcoma.
- ZC3H7B-BCOR endometrial stromal sarcoma constitutes a distinct subtype with high-grade morphology.

2 Platform Presentation: Classifying Undifferentiated Uterine Sarcomas
- Many undifferentiated uterine sarcomas are under-recognized, high-grade endometrial stromal sarcomas with known gene fusions.
- BCOR immunohistochemistry with FISH and/or targeted RNA sequencing may aid in accurate classification of undifferentiated uterine sarcomas.

3 Poster: Novel PLAG1 Gene Rearrangement in Uterine Myxoid Leiomyosarcoma
- Novel PLAG1 rearrangements resulting in PLAG1 expression occur in approximately 25% of myxoid leiomyosarcoma and may serve as a useful biomarker for tumor classification.
Moving Cytogenetics

FORWARD

Cytogenetics Lab Director Yanming Zhang, MD, is passionate about the field and its future at MSK.

By Hope Cristol

Complex karyotype with loss of the short arm of chromosome 17, double minutes and MYC amplification in a patient with AML.

FISH analysis using MYC break-apart probes shows skyline colorful multiple signals all over the interphase nuclei, confirming the double minutes are MYC amplification in chromosome format, which is associated with poor prognosis in AML.

Cytogenetics, which looks at how chromosomes relate to cell behavior, has a relatively long history in pathology. “Cytogenetics has been in practice for more than 50 years, so all the results and their significance have been very solidly confirmed for clinical usage,” says Yanming Zhang, MD, Director of the Cytogenetics Laboratory.

However, the tools and value of this subspecialty have evolved over time, keeping pace with the dramatic changes in the field of pathology. “In the early days of cytogenetics, like the 1970s and 1980s, conventional chromosome analysis was the only test we had,” Dr. Zhang says. “In the 1990s, FISH, or fluorescent in-situ hybridization, became available. Then in the early 2000s, microarray became available. Now we can use these tests together to offer more comprehensive genetic testing and better prediction for patient outcome and treatment selection.”

Dr. Zhang, who oversees a Cytogenetics staff of more than 25 people, recently shared his insight on the current state and his future hopes for Cytogenetics at MSK.

Let’s start with some basic questions. What diagnostic role does cytogenetics have?

Conventional chromosome analysis, FISH analysis and microarray study can find abnormalities that are helpful for diagnosis, prognosis and treatment selection. Many chromosome abnormalities are uniquely associated with subtypes of leukemia, lymphoma and solid tumors. Some abnormalities are associated with good prognosis. Others, unfortunately, are associated with poor outcome and these patients may need more treatment or even clinical trials. Thus, detection of chromosome abnormalities also provides important prediction of treatment response.

FISH analysis of a patient with classical Hodgkin Lymphomas (cHL) showing amplification of PD-L1 and PD-L2 in a Hodgkin and Reed-Sternberg (HRS) cell. PD-L1 and PD-L2 are labeled with orange and green color, respectively. The CEP9 centromere probe is labeled with aqua. The HRS cell with bizarre nucleus shows multiple copies of PD-L1 and PD-L2 as well as CEP9.
Dr. Zhang joined MSK in October 2016 as Director of the Cytogenetics Laboratory. His formal medical education began in China, continued in Germany and concluded with a fellowship at the University of Chicago. He stayed on faculty at UChicago for several years, advancing his career and the field of cytogenetics under the mentorship of the late Janet Rowley, MD, the geneticist best known for describing the Philadelphia chromosome as resulting from a reciprocal translocation between chromosomes 9 and 22.

Dr. Zhang was later recruited by Northwestern University’s Department of Pathology to establish a new clinical cytogenetics laboratory and serve as its medical director. But, nearly six years later, he was offered a position at MSK. “I was very excited. Memorial Sloan Kettering is a very good place for advanced genetic practice, and I was interested in integrating cytogenetics with these new techniques,” Dr. Zhang says.

He oversees routine clinical service, supports research and conducts his own research, especially in collaboration with the Leukemia Service and the Hematopathology Service. In addition, he is an active leader in the cytogenetics community. Since 2013, Dr. Zhang has been Chair of the Eastern Cooperative Oncology Group (ECOG) Leukemia Cytogenetics Committee, overseeing cytogenetics quality and results of multiple leukemia clinical trials from numerous cytogenetics laboratories.
Researching
RARE HEAD AND NECK CANCERS

Nora Katabi, MD, hopes her work leads to better diagnosis and treatment of salivary gland tumors.

By Hope Cristol

As a head and neck pathologist, Nora Katabi signs out rare cancer cases all the time. That’s partly because Memorial Sloan Kettering Cancer Center (MSKCC) is a leader in diagnosing and treating rare diseases, and partly because head and neck cancers are uncommon to begin with, accounting for just 4% of all cancers in the U.S. However, Dr. Katabi’s academic focus is even more specialized: She primarily researches salivary gland malignancies, which make up less than 1% of all cancers in the U.S. This rarity makes them difficult to study in general, but being at “a big center like MSKCC means I am fortunate to be able to see [relatively] many cases for our research,” Dr. Katabi says. The number of study cases is not always sufficient to establish statistical significance, she notes, but she’s hopeful that her research in the pathologic and molecular classification of salivary gland tumors can eventually improve diagnosis and treatment. In her roughly 10-year career, which began as a fellow at MSK, she has published numerous studies advancing the understanding of this rare cancer.

The translocation can separate clear cell carcinoma of the salivary gland from other salivary gland tumors.

COLLABORATIVE DISCOVERIES

One example of an important research effort - with Chief of Experimental Pathology Jorge Reis-Filho, MD, PhD - could ultimately establish a new target for therapy. “I have worked with Dr. Reis-Filho on the characterization of polymorphous adenocarcinoma of the salivary glands,” she says. It’s the second most common type of malignancy in the minor salivary glands. Drs. Katabi, Reis-Filho and others identified a kinase-activating alteration (PRKDI) hotspot mutations) as a likely driver of this cancer.

Early in her career, Dr. Katabi worked with Cristina Antonescu, MD, Director of Bone and Soft Tissue Pathology, to describe an EWSR1-ATF1 fusion in hyalinizing clear-cell carcinoma, a rare, low-grade salivary gland malignancy. The discovery is important because several salivary gland carcinomas have histological overlap, presenting a diagnostic challenge. “This translocation can separate clear cell carcinoma of the salivary glands from other salivary gland tumors,” Dr. Katabi says. Some of her most recent research is on myoepithelial carcinoma, which is an under-recognized, rare, aggressive salivary gland cancer with largely unknown genetic features. In collaboration with MSK surgical oncologist Luc Morris, MD, Dr. Katabi and other researchers comprehensively analyzed molecular alterations in 40 cases. A brief look at their findings, published last October in Nature Communications:

- Myoepithelial carcinoma is low in mutations, high in oncogenic gene fusions
- Most fusions involve the PLAG1 oncogene, associated with PLAG1 overexpression
- FGFR1-PLAG fusions were found in seven (18%) cases
- The novel TGFBR3-PLAG1 fusion was found in six (15%) cases.

Of the many papers that Dr. Katabi has co-authored, including phase I and phase II treatment studies, these are a few that have been published over the past year:

1. Head & Neck: “Patterns of recurrence in oral tongue cancer with perineural invasion.”
3. Human Pathology: “Salivary gland epithelial neoplasms in pediatric population.”
4. Histopathology: “PLAG1 immunohistochemistry is a sensitive marker for pleomorphic adenoma: a comparative study with PLAG1 genetic abnormalities.”
When it comes to the people and circumstances that have shaped the Department of Pathology at Memorial Sloan Kettering Cancer Center (MSK), there are several important truths:

First, there are far too many contributors to describe here with adequate homage.

Second, today’s Pathology staff is driving advances every bit as valuable as those made by celebrated icons of the past.

Further, many of MSK’s fellows are trailblazers in the making. To wit: in the early 1950s, Myron “Mike” Melamed was a fellow who then stayed on as an attending. Surely in those early days he could not have imagined he would become a giant in the field of cytopathology and other aspects of pathology, including the morphogenesis and epidemiology of lung and bladder cancers.

That’s the magic of an institution like Memorial Sloan Kettering Cancer Center. When you attract the brightest and most motivated physicians and scientists and give them support, resources, and freedom to pursue extraordinary visions, the entire field of pathology (and to a large extent, cancer care) takes giant steps forward. It’s been that way for more than 130 years, ever since New York Cancer Hospital – the precursor to MSK – was founded in 1884 as the first institution in the United States exclusively dedicated to cancer care.

**HISTORY OF PATHOLOGY AT MSK**

Snapshots – in words and pictures – from the events and people that forged the foundation of the Pathology Department.

By Hope Cristol
and Marc Rosenblum, MD
At the Women’s Hospital, Dr. Sims had been reprimanded by the Board of Managers for admitting and operating on patients whom he suspected to have cancer. “Board members worried, as did many people at the time, that cancer might be a contagious disease and, in any event, thought that the presence of women doomed to die of cancer could only cause distress to other patients,” Dr. Rosenblum says. “Sims resigned from the hospital he had himself created and lobbied for the realization of what would eventually become MSKCC.”

Meanwhile, the march of progress in medicine continued. Pathologists wrote books, performed autopsies, took academic positions, and traveled near and far to study under leading physicians. Among the field’s rising stars was James Ewing, who became the first professor of pathology at Cornell University Medical School in 1899, a position he held until 1932. Dr. Ewing formed an alliance with prominent mining engineer James Douglas, PhD, then president of the Phelps Dodge Corporation. He was an advocate of the therapeutic potential of radium, discovered in 1898, even after it failed to save his daughter from breast cancer. After her death in 1910, Douglas dedicated his life to promoting “radium therapy” for cancer, and formed the National Radium Institute to mine the substance from uranium ores in Colorado.

Together, Drs. Ewing and Douglas made a proposition to General Memorial Hospital. In exchange for restoring the institution’s focus to cancer care, and committing to radium research and treatment for cancer, Dr. Douglas would donate both money and radium. Dr. Ewing would become president of the medical board, director of research, and pathologist to the hospital. The hospital accepted.

Before long, Dr. Douglas made additional donations and Dr. Ewing became the hospital’s director, a position he held from 1931 to 1939. Among his writings, Dr. Ewing authored Neoplastic Disease, which anchored his position as the preeminent authority on the diagnostic pathology of human tumors. His leadership in the field and at the hospital helped establish Memorial as a leading, if not the leading, free-standing cancer center in the world.

Though, of course, there have been many contributors to the institution’s excellence in pathology, it can be said that in the earliest years, these two helped launch pathology’s rise to prominence here.

OTHER NOTEWORTHY FIGURES FROM THE OLD GUARD

There’s practically encyclopedic breadth and depth of information about the history of pathology at MSK. It dovetails, naturally, with the history of pathology in general, as well as scientific innovations. Here is a brief, and by no means comprehensive, look at influencers from the “old guard” – well before the 1960s.

Elise Strang l’Esperance: Dr. l’Esperance, who was particularly interested in early cervical cancer, joined Dr. Ewing at Memorial Hospital. She was a proponent of the cervicovaginal smear technique for cancer screening and a firm supporter of Papanicolaou.

In 1943, she donated two Technicon tissue processors to the Pathology Department. In 1945, she established at Memorial Hospital and the New York Infirmary two Strang Prevention Clinics. The first clinical cytology lab, established at the Strang Clinic, would become the Cytology Service of the Department of Pathology.

Fred Stewart: Dr. Stewart became Ewing’s assistant in 1927 and head of the Pathology Department in 1939. He was renowned for his diagnostic excellence. Stewart’s consultations were brief, to the point, and highly sought out, particularly for problem cases. (He typed all his own personal and professional correspondence on an Underwood typewriter, which sat on a metal stand on wheels.)

The American Cancer Society would eventually recruit Dr. Stewart as Founding Editor of the Journal Cancer, which appeared in 1948 as the first periodical devoted solely to studies in the pathology, pathogenesis, and treatment of neoplastic diseases. The first edition included articles co-authored by Dr. Stewart that established the criteria for the diagnosis of post-radiation sarcomas, and that defined the entity of lymphangiosarcoma arising in the setting of post-mastectomy lymphedema (Stewart-Treves syndrome).

Dr. Stewart and his students described a number of other tumor entities and he produced Tumors of the Breast (1950), the first Armed Forces Institute of Pathology (AFIP) Fascicle devoted to mammary neoplasia. August Wadsworth: Head of the Division of Laboratories and Research at the New York State Department of Health in Albany, he approached Drs. Stewart and Ewing for help improving the performance of other pathology labs across the state. This was during the 1930s, and board certification for pathology would not become common until the 1960s.
ELISE STRANG L’ESPERANCE, MD
The first clinical laboratory of cytology, established at the Strang Cancer Prevention Clinic, subsequently became the Cytology Service of the Department of Pathology.

SOPHIE SPITZ, MD
Spitz produced the monumental, beautifully illustrated atlas, *Pathology of Tropical Diseases*.

Her term “juvenile melanoma” became synonymous with her name and was renamed “Spitz nevus”.

MSKCC DEPARTMENT OF PATHOLOGY:
FACULTY & FELLOWS (MEN & WOMEN), 2018

Learn more about the history of women in our department and their profound achievements and contributions in our 1Q19 issue.

*Faculty featured in this section hold a “Director” title
STORIED ARCHITECTURE

Even the physical structure of MSK has an architecturally significant and storied past. The original building, located on the corner of 106th Street and Central Park West in Manhattan, was inspired by a French chateau. Four large, conical towers each housed beds in a circular fashion, in part to improve surveillance of the patients. At least according to lore, a displeased public called it the “Bastille of Central Park.”

In 1939, the hospital moved to a new building at 444 East 68th Street, built on land donated by John D. Rockefeller Jr. In 1948, The Sloan-Kettering Institute (SKI) opened on adjacent land. This research arm of the hospital was established thanks to the vision of hospital director Cornelius P. “Dusty” Rhoads and the generosity of Alfred P. Sloan and Charles F. Kettering. It would be another 12 years before the institution took on its current name and function. In 1959, the combined hospital and research institute were named Memorial Center for Cancer and Allied Diseases. Finally, in 1960, Memorial Sloan-Kettering Cancer Center was incorporated, with SKI and the hospital as its two major entities.

Dr. Foote was a gifted diagnostician and produced, among many notable works, Tumors of the Major Salivary Glands (1954). It was co-authored with head and neck surgeon Edgar Frazell and the first AFIP Fascicle devoted to lesions of this type.

Sophie Spitz: The Spitz nevus was named for this part-time pathologist at Memorial. She originally termed the childhood skin lesion “juvenile melanoma” in a 1948 paper. However, it would come to be closely associated with her and eponymously renamed.

As is a tale, so is a life: Not how long it is, but how good it is, is what matters.”

– Seneca
1866

First pathology laboratory established at Roosevelt Hospital

1871

Hospital name changed to the “General Memorial Hospital for the Treatment of Cancer and Allied Diseases”

1887

106th Street location opens as the “New York Cancer Hospital”

1895

Formalin fixation proposed by TS Cullen at Johns Hopkins

1898

Dr. James Ewing becomes the pathologist for the General Memorial Hospital for the Treatment of Cancer and Allied Diseases

1913

Drs. James Douglas and James Ewing propose a permanent affiliation with Cornell in exchange for a gift of $100,000, several grams of radium (then worth $100,000/gram), equipment to set up an X-Ray treatment facility and clinical laboratory.
Hospital name changed to “Memorial Hospital for the Treatment of Cancers and Allied Diseases”

Dr. Elise Strang l’Esperance joins the Pathology Department

Laboratory established on premises

John D. Rockefeller offers an annual donation of $60,000 to “enhance teaching efforts at Memorial Hospital”

Flemming discovers penicillin

Augustus Wadsworth (head of the Division of Labs and Research at the New York State Department of Health in Albany, NY) approaches Drs. Ewing and Stewart for assistance in establishing a system of state approval and support for county laboratories.

Dr. James Ewing is featured on the cover of Time Magazine
1932
Amelia Earhart flies across the Atlantic Ocean

1938
New location at 444 East 68th Street is opened

1939
Dr. Frank Foote joins the department as a fellow
Dr. Fred Stewart is appointed Chairman of the Department of Pathology

1941
US enters WWII

1945
Dr. Elise Strang l’Esperance establishes two Strang Cancer Prevention Clinics which later become the Cytology Service in the Department of Pathology
Research arm of hospital established as the "Sloan Kettering Institute"

Journal Cancer is published which is sponsored by the American Cancer Society. Dr. Fred Stewart serves as Editor.

Combined centers are named "Memorial Center for Cancer and Allied Diseases"

First open heart surgery

Establishment of flow cytometry at MSKCC

NY Board certification in pathology and cytology with proficiency exams established with the help of Memorial Hospital Pathology staff.

FRANK FOOTE, JR., MD
1959-1972

President John F. Kennedy assassinated

Civil Rights Act of 1964

President John F. Kennedy

1960

1957

1956

Elvis Presley performs on the Ed Sullivan Show

1952

1948

Emblem of the hospital

1950

1963

1948

1964
1965

Introduction of the electron microscopy at MSKCC

1969

Neil Armstrong walks on the moon

Cytotechnology training program, first established in the early 1950’s, is officially recognized as the School of Cytology under the leadership of Dr. Leopold Koss and Mrs. Grace Dufree.

1973

Main Campus location opens at 1275 York Avenue

1974

President Nixon resigns

1976

1981

Sandra Day O’Connor is sworn in as the first woman Supreme Court justice.

1985

FISH (fluorescence in situ hybridization) introduced

Scientists develop a method that combines microarray technology with a form of artificial intelligence which enables physicians to tell the difference between four childhood cancers — neuroblastoma, Ewing’s sarcoma, non-Hodgkin lymphoma and rhabdomyosarcoma.

2001

Introduction of biobanking at MSKCC

PATRICK J FITZGERALD, MD
1972 - 1979

MYRON “MIKE” MELAMED, MD
1979 - 1989

JUAN ROSAI, MD
1991 - 1999
If you’re outside the Department of Pathology, you may be unfamiliar with the names Mike Melamed, Juan Rosai, Philip Lieberman, Stephen Sternberg. Inside the department, it’s a vastly different story. Around here, indeed across the entire field of pathology, they are legendary.

These and several other pathologists (along with a few others, including Drs. William Gerald and Willet Whitmore) made extraordinary contributions to pathology during their time at MSK. They also mentored some of today’s department leaders, including Dr. Rosenblum; Pathology Chair David Klimstra, MD; Pathology Vice Chair Victor E. Reuter, MD; and Molecular Diagnostics Service Chief Mark Ladanyi, MD.

Their scientific impact cannot be overstated. In due time, it is likely that each of them will be extensively celebrated and memorialized in the literature of pathology.”

Their scientific impact cannot be overstated. In due time, it is likely that each of them will be extensively celebrated and memorialized in the literature of pathology.”

The New England Journal of Medicine that confirmed the association between smoking and lung cancer.

One of his most significant, pioneering contributions to cytometry was his seminal 1969 paper in Science, titled “Spectrophotometer: New Instrument for Ultra-rapid Cell Analysis.” Dr. Melamed (along with his friend at Columbia University, Louis A. Kamentsky) described the first flow cytometer that provided multiparameter analysis. Specifically, ultraviolet absorption and visible light scatter were measured simultaneously, enabling the display of two-dimensional histograms. The instrument, developed in an effort to measure the DNA ploidy of cells, became the basis for the next generation of flow cytometers.

“Dr. Melamed was an exemplary physician-scientist. While directing a remarkably far-sighted research program in quantitative and automated cytology, he took his regular turns with the rest of the staff on the Surgical Pathology and Cytology Services. He was a skilled diagnostician and teacher,” Dr. Rosenblum says. “More than a few owe the launching of their academic careers to Dr. Melamed, who effectively placed the future of genitourinary pathology at MSKCC in the hands of a young Victor Reuter and who challenged me to reinvent myself as a neuropathologist.”

Dr. Melamed passed away in 2013 of pancreatic cancer – though he beat the long odds for a while, surviving with the devastating disease for more than six and a half years.

Juan Rosai. Our institution was fortunate to have Dr. Rosai serve as Department of Pathology Chair from 1991 to 1999. He is the author or coauthor of numerous publications and other important works, including Rosai and Ackerman’s Surgical Pathology, the 2nd Series AFIP Fascicle on Tumors of the Thymus, and the 3rd Series AFIP Fascicle on Tumors of the Thyroid. He is also the editor of the Second Edition of the W.H.O. book on Histologic Classification of Thymic Tumors, as well as editor of the book Guiding the Surgeon’s Hand: The History of American Surgical Pathology.

Other career achievements include the characterization of rare medical conditions. These include desmoplastic round-cell cancer and a type of histiocytosis known as Rosai-Dorfman disease. Despite his obviously demanding and rigorous schedule, he managed to serve as a wonderful mentor to many, and today is known for that as well.
In an interview with *The Pathologist*, Dr. Klimstra recalls how Dr. Rosai influenced his decision to focus on pancreatic neoplasia many years ago. When Dr. Klimstra was a resident at Yale, he encountered a rare case of pancreatic acinar cell carcinoma. Back then it required electron microscopy to confirm the diagnosis. Dr. Rosai had told him there were no immunohistochemical markers for it, and certainly no comprehensive studies on it, so he encouraged Dr. Klimstra to assemble a series of cases and review the collection of the US Armed Forces Institute of Pathology. During and after this study, Dr. Klimstra was struck by the dearth of American pathologists studying pancreatic cancer, and he decided to help fill in the gap. Remarkably enough, that single uncommon case of pancreatic acinar cell carcinoma in 1989 sparked an interest in pancreatic neoplasia that continues to this day.

**The (many) others.** What about Drs. Sternberg, Lieberman, and other major influencers on the field? They, too, are deserving of pages not available here. Dr. Sternberg was a surgical pathologist at this institution for nearly 50 years, Chief of the Autopsy Service, and a recipient of the 2001 Fred Waldorf Stewart Award for his contributions to progress against human neoplastic diseases. He was also Founding Editor of *The American Journal of Surgical Pathology*, which became the leading publication venue for academic surgical pathologists for many years. Dr. Lieberman, a World War II veteran, was the Chief of Surgical Pathology, co-author (with Leopold Koss) of *Guiding the Surgeon’s Hand*, and author of many papers on both human and veterinary pathology. These and many other past leaders in our Pathology Department have not only helped shape pathology as we know it today, but also groomed - directly and indirectly - the pathologists who are making history at the microscope right now.

**Editorial Acknowledgements:** Mary Ann Friedlander, Drs. Achim Jungbluth, David Klimstra, Victor Reuter and Marc Rosenblum

**MORE THAN PATHOLOGISTS**

The Department of Pathology’s recent leaders weren’t just brilliant. They were also fun, and there are pictures that capture some of the joyful moments when they were around.

In one, Dr. Sternberg smiles for the camera while holding a small goat. In another, Drs. Reuter, Lieberman, Sternberg, Melamed, and Rosenblum scrunch side-by-side on a couch, their arms around each other. And there’s this classic: Dr. Rosai bowing to kiss Dr. Reuter’s hand as the men practiced protocol for meeting the Pope.

These snapshots may not characterize their clinical or research impact, but they reveal a fun and collegial mood in their presence – and that is certainly part of the history of Pathology at MSK.
REPORT OF THE PATHOLOGIST.

To the Medical Board of the New York Cancer Hospital:

Gentlemen—During the year ending December 31, 1888, I have had referred to me for microscopical examination fifty-five (55) specimens. The diagnoses founded upon the examinations are given in the following table:

<table>
<thead>
<tr>
<th>Diagnosis (description)</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carcinoma (infiltrative) of the breast</td>
<td>27</td>
</tr>
<tr>
<td>of the galbladder</td>
<td>1</td>
</tr>
<tr>
<td>of the uterus</td>
<td>3</td>
</tr>
<tr>
<td>of the ovary (against)</td>
<td>1</td>
</tr>
<tr>
<td>Sarcoma of the breast</td>
<td>1</td>
</tr>
<tr>
<td>of the uterus</td>
<td>1</td>
</tr>
<tr>
<td>of the ovary</td>
<td>1</td>
</tr>
<tr>
<td>Intestinal metastases of the breast</td>
<td>1</td>
</tr>
<tr>
<td>Adenoma of the breast</td>
<td>1</td>
</tr>
<tr>
<td>Tubular adenoma growing into a cyst of the breast</td>
<td>1</td>
</tr>
<tr>
<td>Epithelioma of the ovary</td>
<td>1</td>
</tr>
<tr>
<td>of the uterus</td>
<td>1</td>
</tr>
<tr>
<td>of the cervix</td>
<td>1</td>
</tr>
<tr>
<td>Fibroma of the ovary</td>
<td>1</td>
</tr>
<tr>
<td>of the breast</td>
<td>1</td>
</tr>
<tr>
<td>Cyst of the breast</td>
<td>1</td>
</tr>
<tr>
<td>Chronic mastitis</td>
<td>1</td>
</tr>
<tr>
<td>Epidermoid</td>
<td>1</td>
</tr>
<tr>
<td>Desmoma of the ovary</td>
<td>1</td>
</tr>
</tbody>
</table>

Total: 55

The results of five autopsies are as follows:

<table>
<thead>
<tr>
<th>Diagnosis (description)</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carcinoma (secondary) of the liver</td>
<td>1</td>
</tr>
<tr>
<td>Epithelioma of the scalp, loose of the skull, albumen of brain</td>
<td>1</td>
</tr>
<tr>
<td>General paralytic following a stroke of the sigmoid flexure, chronic meningitis</td>
<td>1</td>
</tr>
<tr>
<td>Secondary tumors of the pons, lungs, and liver</td>
<td>1</td>
</tr>
<tr>
<td>Carcinoma of the uterus, metastases miliary involving all internal organs, dilatation of the breast and point of the kidney, chronic diffuse nephritis</td>
<td>1</td>
</tr>
</tbody>
</table>

Total: 5

New York, January 1, 1889.
G. C. Freedborn.
Why is teaching so important to you?
Teaching is important to me because I love the challenge of getting someone to learn something that they may not have known before. I enjoy the challenge of recognizing different learning styles and modifying my teaching style to get to the message across to the learner. I enjoy developing different educational resources to enhance the learning process. Making that connection is not always so easy and requires patience but when it is successful, it is very rewarding.

Are you still able to incorporate education in your current role?
Even though formal teaching is no longer my primary job, I try to incorporate teaching in my current role. My team and I have presented several QA educational sessions on regulatory compliance topics, thematic QA events, quality improvement and internal and external inspections. Our hope in sharing this information is not only to engage and enlighten staff, but to gain their active involvement in developing and maintaining quality practices.

MSK is the kind of place where people tend to stay, yourself included. What has kept you here for so long?
I think if my first job in cytology were at a different institution, I probably would have gone back to school and likely be doing something else. MSK Pathology is an incredible place to work. Our case mix and the experts that I work with have all made for a fulfilling work experience. I am grateful that I have always had great mentors in every job I’ve had, who mirror what it is to grow professionally.

Outside of MSK, I also volunteer in several professional societies. This has provided me the opportunity to expand my knowledge beyond the microscope and acquire skills I wouldn’t have otherwise gained sitting at my desk behind the microscope or computer all day. I have managed several projects, presented workshops, fostered professional relationships and continue to learn from colleagues at other institutions. This combined experience is what prepared me for each job at MSK.

What does a Quality and Regulatory Manager do in the Department of Pathology?
Our Quality Assurance (QA) team is responsible for overseeing QA activities and monitoring regulatory compliance of all Pathology laboratories, including our off-site labs. We work closely with the Pathology QA chairs and lab leadership to collect and monitor a variety of lab-defined quality metrics. This data includes specimen submission deficiencies, turnaround time, amended reports and diagnostic discrepancies. We track monthly metrics, investigate non-conformances and look for opportunities to enhance quality and patient safety.

We also facilitate internal and external laboratory inspections and work with lab management to address identified deficiencies, investigate non-conformances and ensure robust, effective corrective actions. We monitor corrective actions of citations from past inspections for continued effectiveness. Hopefully, when inspectors come to the laboratories, we will have minimal to no citations because we operate at continual readiness.

What other positions have you had at MSKCC?
I have been fortunate to have several opportunities to grow professionally here. I started as a student in the MSK School of Cytotechnology and stayed on as a staff cytotechnologist. I soon became the Education Coordinator of the school and enjoyed the combination of clinical work and teaching cytotechnology to students and fellows. My interest in accreditation occurred when I was the Education Coordinator. Running a school extended beyond teaching. I learned the administrative requirements of a running a training program. I eventually moved on to become the Cytology Lab Manager. Managing laboratory operations was very different than teaching, but during this time, I realized I really enjoyed quality management and regulatory compliance. Eventually, the Quality and Regulatory Manager position arose in the department and allowed me to have an opportunity to work more closely in these areas.

Looking back on your 25+ years at MSK, what are some of your favorite parts of the work?
Working in cytotechnology was always stimulating. I enjoyed microscopic work, hunting for significant cells and correlating morphology with clinical information to determine the best diagnosis for the patient alongside the pathologist. I enjoy the fact that pathology has evolved so much. As an educator, you have to be on your toes when students ask questions and keep up with all the changes in the field.

In my current role, I enjoy event investigations and problem solving. I enjoy evaluating and simplifying complicated processes to make them more efficient, without compromising quality or end results. I find it rewarding to work collaboratively with all lab staff at finding solutions and improving the quality of what we do.
The development of Genitourinary Pathology at MSK

By Hope Cristol

There are just a few pathologists who have worked in the Pathology Department for more than three decades. Victor Reuter, MD, is one of them. He is Vice Chair of the Department of Pathology, Team Leader of the Genitourinary Pathology team in the Department of Pathology, Team Leader of the Genitourinary Pathology Department, and Director of the Genitourinary Pathology Fellowship.

You’d expect Dr. Reuter to be a rich source of information about pathology at MSK – and he is. What may come as a surprise though, is just how enthusiastic he can be about it.

Dr. Reuter is energized by the achievements and possibilities of modern pathology. He’s admiring of his colleagues’ talent. He talks with reverence about his pathology. He’s admiring of his colleagues’ achievements and possibilities of modern pathology at MSK – and he is. What may come as a surprise though, is just how enthusiastic he can be about it.

Dr. Reuter is looking for, and looking forward to, eventual answers to questions like: When can a renal tumor can be left alone and not necessarily resected? When is it that the two part-time oncology surgical pathology subspecialties at MSK, comprising approximately 17% of all cases accessioned in pathology. That’s where the two part-time members of the GU team come in. GYN pathologist Sarah Chiang, MD, and Director of Pathology Informatics Joseph Sirintraphun, MD, both have training and interest in GU pathology, so they play an important role signing out cases on the GU team.

Looking ahead

After 35 years in the field and countless achievements, Dr. Reuter still does not feel he has come close to reaching his interest in or potential for contributions to the field. “What keeps things interesting is that on a weekly basis, we have additional information that comes to bear on our diagnosis. These are the things that we’re working together to classify a tumor, or to establish risk or response to therapy.”

Dr. Reuter says.

That last part – establishing which patients are best suited for a specific therapy – is the modern-day holy grail of pathology. There are big efforts going on in our institution to try to address that at the molecular level, but I don’t think we’re close to solving the problem. That’s aspirational.”

Dr. Reuter is looking for, and looking forward to, eventual answers to questions like: When can a renal tumor can be left alone and not necessarily resected? When is it that the two part-time oncology surgical pathology subspecialties at MSK, comprising approximately 17% of all cases accessioned in pathology. That’s where the two part-time members of the GU team come in. GYN pathologist Sarah Chiang, MD, and Director of Pathology Informatics Joseph Sirintraphun, MD, both have training and interest in GU pathology, so they play an important role signing out cases on the GU team.

Dr. Reuter helped recruit pathologists with an interest in translational research to round out the GU team. The first of this group was Anuradha Gopalan, MD, who started at MSK as a fellow and then spent time in the lab of the late William Gerald, MD, PhD, working on prostate cancer. “She published seminal papers on aspects of molecular biology and clinical repercussions in prostate cancer,” Dr. Reuter says.

After her, Hikmat Al-Ahmadie, MD, joined the staff. A prior fellow in oncologic surgical pathology and GU pathology, “he went to practice at University of Chicago and then he came back as our bridge to the translational efforts in bladder cancer,” Dr. Reuter says.

Finally, Yingbei Chen, MD, became the team’s bridge to kidney translational research. “She’s produced seminal papers in that area and has developed a very good relationship with members of other departments focused on kidney cancer,” Dr. Reuter says.

It would seem the GU team was complete. Dr. Reuter felt it was strong diagnostically, in translational research and in collaborative relationships. There was just one problem: the increase in clinical volume in one of the busiest subspecialties at MSK, comprising approximately 17% of all cases accessioned in pathology. That’s where the two part-time members of the GU team come in. GYN pathologist Sarah Chiang, MD, and Director of Pathology Informatics Joseph Sirintraphun, MD, both have training and interest in GU pathology, so they play an important role signing out cases on the GU team.

"These are the things that as a pathologist interest me the most - not only who needs systemic therapy but who can we actually treat more conservatively."
RESEARCH SPOTLIGHT

The pathologist shares her latest research on two new screening approaches for pan-cancer targetable molecular events.

JACLYN HECHTMAN, MD

By Hope Cristol

At the 2018 United States & Canadian Academy of Pathology (USCAP) meeting in Vancouver, pathologist Jaclyn Hechtman, MD, spoke on a panel for Medscape Education. The topic was Evolving Diagnostics Standards in Characterizing Cancer, with an emphasis on testing treatment-naive cancers for rare alterations that are targetable. It gave Dr. Hechtman an ideal opportunity to share some of her recently published work.

Dr. Hechtman is an assistant attending physician on the Gastrointestinal (GI) Pathology team and the Molecular Diagnostics Service. Her primary research interest is in the molecular characterization of colorectal carcinomas. “Being that I practice both surgical and molecular pathology, I also participate in assay validation,” she says. “When collaborating with clinicians, I’m often the team member who selects the appropriate assay and/or interprets multiple different assays across surgical and molecular pathology.”

Dr. Hechtman has investigated under-represented driver alterations in colorectal carcinoma including 20q amplification (Molecular Cancer Research, 2017), SOX9 mutations (Oncotarget, 2016), recurrent AKT1 mutations (Molecular Cancer Research, 2015), and under-represented fusions and activating mutations (Molecular Cancer Research, 2016) in her time at MSK. However, at the USCAP/Medscape presentation in March, it was all about her two latest papers: one on pan-Trk immunohistochemistry for neurotrophic tyrosine receptor kinase (NTRK) fusions (American Journal of Surgical Pathology, 2017), and another on getting microsatellite instability (MSI) status from next-generation sequencing data (Journal of Clinical Pathology Precision Oncology, 2017).

NTRK FUSION SCREENING

Immunohistochemistry (IHC) has certain advantages over next-generation sequencing (NGS) of DNA or RNA, such as lower costs and faster turnaround time. There’s also the matter of expertise. It can be technically difficult to extract RNA and perform NGS, whereas IHC is widely used across pathology labs.

MSK oncologists David Hyman, MD, and Alexander Drilon, MD, recently led a clinical trial investigating the use of larotrectinib for NTRK-fusion positive cancers. The results showed “marked and durable antitumor activity,” (New England Journal of Medicine, 2018). As a collaborator in the study, Dr. Hechtman worked with the Diagnostic Molecular Pathology and Developmental IHC labs to explore the utility of pan-Trk IHC to detect these targetable NTRK fusions, which define certain rare cancers and are also present in low numbers in very common cancers. The results were promising:

• Pan-Trk IHC was positive in 20 of 21 cases with NTRK fusion transcripts confirmed by Archer fusion testing (sensitivity for transcribed fusions of 95%).
• 20 Archer-negative cases all had concordant pan-Trk IHC results (specificity for transcribed fusion of 100%).
• 2 cases with DNA level NTRK rearrangements with negative Archer results were also negative for pan-Trk IHC.

“Pan-Trk IHC is making screening for this particularly treatable fusion much faster and more accessible,” Dr. Hechtman says. “It also carries the benefit of protein-level expression, which is likely to be functional and oncogenic.”

Although commercially available, pan-Trk IHC isn’t widely used in surgical or molecular pathology – yet. The results of the recent larotrectinib trial for NTRK-fusion positive cancers will likely result in an increase in screening of driver negative cancers for NTRK fusions.

MICROSATELLITE INSTABILITY SCREENING

Microsatellite instability (MSI)/ mismatch repair (MMR) status has several clinical implications, including response to immune checkpoint inhibitors and the potential need for additional testing for Lynch syndrome. That’s why the National Comprehensive Cancer Network recommends screening for all patients with colorectal cancer and for patients with uterine endometrioid cancer who are at risk for Lynch syndrome.

“MMR IHC and MSI PCR are the most commonly used assays in many labs. However, with next generation sequencing being performed in many of the advanced cancers at MSKCC, we decided to build MSI status into our NGS panel,” Dr. Hechtman says.

They turned to MSK-IMPACT and inferred MSI status from more than 12,000 solid tumors using MSisensor, a program that reports the percentage of unstable microsatellites as a score. The researchers found that obtaining MSI status from MSK-IMPACT is both possible and reliable. It also resulted in an unexpected number of rarer cancers with MSI-H status: 35% of all MSI-high tumors were not colorectal or uterine endometrioid carcinomas.

“This addition to MSK-IMPACT makes it possible for us to screen all patients who receive NGS testing for MSI-H status without additional testing,” Dr. Hechtman says. “If the patient’s tumor is MSI-H, there may be significant changes to patient management, including potential eligibility for immune checkpoint inhibitor therapy and discussions regarding further germline testing for Lynch syndrome.”

“MMR IHC and MSI PCR are the most commonly used assays in many labs. However, with next generation sequencing being performed in many of the advanced cancers at MSKCC, we decided to build MSI status testing into our NGS panel...”

- Jaclyn Hechtman, MD
John Iafrate, MD, PhD, is the Director of the Center for Integrated Diagnostics at the Massachusetts General Hospital (MGH) and Professor of Pathology at Harvard Medical School. He is a native New Yorker and received his M.D. and Ph.D. degrees from Stony Brook University in 2000. He trained in anatomic and molecular genetic pathology at Brigham and Women’s Hospital. During his postdoctoral work at the Brigham, John discovered copy number variations - copy number gains or losses of large genomic regions - as a novel source of human genetic diversity.

John joined the MGH pathology staff in 2005 and established the clinical laboratory for molecular diagnostics with the fundamental goal of developing high-throughput genetic screening approaches for all cancer patients. The molecular diagnostics laboratory expanded impressively under his direction. His laboratory launched SNaPshot, a multiplex mutational profiling assay covering over 100 most common mutations in tumors to help direct novel targeted therapies. His laboratory also developed next-generation sequencing-based Anchored Multiplex PCR that detects gene fusion events from clinical specimens. Both of these techniques have been extensively used in the molecular diagnostics community.

John has also led major laboratory efforts particularly in the areas of lung and brain cancers as well as human germline genetics. He played a pivotal role in the recent development of small molecule kinase inhibitors for lung tumors with ALK and ROS1 tyrosine kinase rearrangements. His laboratory was also the first to discover tumor genetic heterogeneity in glioblastoma by studying gene amplification of receptor tyrosine kinases. John’s interests transcend those related to biological discoveries, and he has led studies that resulted in the development of novel molecular techniques to address unmet pathology and medical needs.

“His commitment to personalized cancer care embodies a key principle of modern day medicine – of looking at disease through the genetic lens.”

John has been a superb educator and supportive mentor for countless pathology trainees, and a gifted speaker. He is a gifted and creative investigator whose selfless humility lends to numerous collaborative studies. His commitment to personalized cancer care embodies a key principle of modern day medicine – of looking at disease through the genetic lens.

- Jorge Reis-Filho, MD, PhD
NATIONAL MEDICAL LABORATORY PROFESSIONALS’ WEEK 2018

This year’s National Medical Laboratory Professionals’ Week took place from April 22- April 28, 2018. The celebration included a wide variety of activities, events and educational lectures that served as a platform to showcase the impressive and vital work performed by our dedicated lab staff here at Memorial Sloan Kettering Cancer Center.

HERE WERE THE HIGHLIGHTS:

LECTURES
“THE CURIOUS CASES OF LABORATORY MEDICINE”
Drs. Patrick Erdman, Stephanie Forest and Lauren Moore

“DECODING COLORECTAL CANCER: THE IMPORTANT ROLE OF PATHOLOGY AND LABORATORY MEDICINE”
Dr. Jinru Shia

“THE 2018 MEDICAL LABORATORY PROFESSIONALS WEEK FEATURE LECTURE”
Keynote Speaker: Dr. Craig Thompson, MSKCC President and CEO

“CARS AND ARMORED CARS”
Dr. Renier Brentjens

“How Digital Pathology Can (And Will) Transform the Laboratory”
Dr. Matthew Hanna

LAB WEEK FAMILY FEUD CHALLENGE WINNERS:
1st Place:
- Nana Mensah
- Alejandra Pierre-Louis
- Anita Yun
- Paulo Salazar
- Meiyi Wang

2nd Place:
- Francine Johnson
- Donna Marie Vastaro
- Amanda Ly
- Kalsang Shrestha
- Shannon Kessy
- Shannon Hall
- Stanley Polich
- Jum Chan
- Alexander Gilbert

TALENT SHOW:
1st Place:
- Joel Polo, Mauricio Delgado and Steve Tulumba

2nd Place:
- Kuntal Kumar Serval

3rd Place:
- Kelsey Turner, Elise Feuer, Danielle Kehn

PHOTO CONTEST:
1st Place:
- Sean McNair

2nd Place:
- Nataly Bermeo

3rd Place:
- Kelsey Turner, Elise Feuer, Danielle Kehn

(Photos featured below)
FELLOWS’ FEATURE

It has been a privilege for us to work with all of you this past year. Teaching fellows is certainly part of the core mission of our department, and it is very rewarding to work with bright pathologists who challenge our concepts and keep us sharp every day. We also understand that training here as a fellow involves a lot of hard work! You have shown outstanding dedication and professionalism - it is no understatement that our jobs and your jobs have been so intertwined, it is hard to conceive of them separately - it has been a true partnership. I hope that the experience you have gained - both from the unusual cases you encountered here and from the more routine case material - will help you transition from trainees to attending and develop the confidence you will need as you go out into the “real world” of independent practice. Wherever you go, you will carry this fellowship experience with you. Don’t be surprised if, in your first few weeks of practice, your new senior colleagues seek your opinion about challenging cases. You have trained at Memorial, and everyone knows that you now bring a higher level of expertise to the diagnosis of cancer. So, with thanks, I bid you best wishes for your future, and I hope we will see all of you again at our alumni reunions and other professional events.

David Klimstra, MD
Chair, Department of Pathology; James Ewing Alumni Chair of Pathology

Congratulations and Best Wishes to all! You are an awesome group! Enjoyed working with you!

Meera Hameed, MD
Chief, Surgical Pathology Service

You have worked hard and endured a tough journey this past year. Congratulations: You made it! This class has truly been a gem. We are grateful for all the contributions you have made to our department and our patients. We are certain that you’ll always look back on graduating from the Oncologic Surgical Pathology Fellowship as one of the major accomplishments in your life. We are proud to have you as Memorial alumni.

Melissa Murray, DO & Nora Katabi, MD

Done ✓ (at last).

Victor Reuter, MD
Vice Chair, Department of Pathology; Director, Genitourinary Pathology; Director, Genitourinary Pathology Fellowship; Director, Pathology Core Facility

FUTURE PLANS

ISABELLE CUI
Gastrointestinal Pathology Fellowship, University of Iowa

CHRISTIAN CURCIO
Bone and Soft Tissue Pathology Fellowship, MD Anderson

ANDREW GOLDEN
Thoracic Pathology Fellowship, MSKCC

LAURA FAVAZZA
Molecular Genetics Pathology Fellowship, University Pittsburgh Medical Center

MATTHEW HANNA
Attending Pathologist, MSKCC

PATRICK HENN
Gastrointestinal Pathology Fellowship, University Pittsburgh Medical Center

LIWEI JIA
Genitourinary Pathology Fellowship, MSKCC

UPASANA JONEJA
Gastrointestinal Pathology Fellowship, University of Pennsylvania

BRIE KEZLARIAN
Cytopathology Fellowship, MSKCC

DANIEL LEVITAN
Gynecologic and Perinatal Pathology Fellowship, NY Presbyterian/Weil Cornell

STEPHANIE MULLER
Cytopathology Fellowship, MSKCC

PALLAWINNAGE VIDARSHI MUTHUKUMURANA
Molecular Pathology Fellowship, University of Chicago

MARYAM SHAHI
Gastrointestinal Pathology Fellowship, MSKCC

JAMES SOLOMON
Attending Pathologist, Permanente Medical Group, CA

MONIKA VYAS
Surgical Pathology Fellowship, John Hopkins

SABINA HAJIYEV
Attending Pathologist, University of British Columbia

ZENA JAMEL
Attending Pathologist, Lenox Hill

KANT MATSUDA
Attending Pathologist, George Washington University

DEEPU ALEX
Attending Pathologist, University of California San Diego

TIANHUA GUO
Attending Pathologist, Quest Laboratories, CA

LEILI MIRSADRAEI
Attending Pathologist, Queen’s University/Kingston Health Sciences Centre

BRIANNE DANIELS
Attending Pathologist, MSKCC

ALLEN MIRAFLOR
Attending Pathologist, MSKCC

TAO WANG
Attending Pathologist, Koo Foundation Sun Yat-Sen Cancer Center

YU-CHING PENG
Attending Pathologist, MSKCC

GULISA TURASHVILI
Attending Pathologist Mount Sinai Hospital Toronto

PALLAVI KHATTAR
Attending Pathologist, MSKCC

FATIMA JELLOUL
Attending Pathologist, MD Anderson

PRIYADARSHINI KUMAR
Advanced Hematopathology Fellowship, MSKCC

NATASHA LEWIS
Attending Pathologist, MSKCC

JAVIER ARIAS - STELLA
Attending Pathologist, University of California San Diego

JASON CHANG
Attending Pathologist, MSKCC

PAOLO COTZIA
Attending Pathologist, NYU Winthrop Hospital

SOUNAK GUPTA
Genitourinary Pathology Fellowship, MSKCC

CHAD VANDERBILT
Cytopathology Fellowship, Baylor College of Medicine

STEPHANIE MULLER
Attending Pathologist, MSKCC

SABINA HAJIYEV
Attending Pathologist, MSKCC

JAYANTI JAIN
Attending Pathologist, NY Presbyterian/Weil Cornell

SUJATA SINGH
Attending Pathologist, MSKCC

SABBIN HAJIYEVA
Attending Pathologist, Texas Health Presbyterian Hospital Dallas

MARYAM SHAHI
Attending Pathologist, MSKCC

JAMES SOLOMON
Molecular Pathology Fellowship, MSKCC

MONIKA VYAS
Gastrointestinal Pathology Fellowship, MSKCC

YOURAN ZOU
Attending Pathologist, Permanente Medical Group, CA

SABINA HAJIYEV
Surgical Pathology Fellowship, MSKCC

ZENA JAMEL
Attending Pathologist, Lenox Hill

KANT MATSUDA
Attending Pathologist, George Washington University

DEEPU ALEX
Attending Pathologist, University of British Columbia

TIANHUA GUO
Attending Pathologist, CBL Path

LEILI MIRSADRAEI
Attending Pathologist, NYU Winthrop Hospital

BRIANNE DANIELS
Attending Pathologist, University of California San Diego

ALLEN MIRAFLOR
Attending Pathologist, Quest Laboratories, CA

TAO WANG
Attending Pathologist, Queen’s University/Kingston Health Sciences Centre

YU-CHING PENG
Attending Pathologist, Koo Foundation Sun Yat-Sen Cancer Center

GULISA TURASHVILI
Attending Pathologist Mount Sinai Hospital Toronto

PALLAVI KHATTAR
Attending Pathologist, MSKCC

FATIMA JELLOUL
Molecular Pathology Fellowship, MD Anderson

PRIYADARSHINI KUMAR
Advanced Hematopathology Fellowship, MSKCC

NATASHA LEWIS
Attending Pathologist, MSKCC

JAVIER ARIAS - STELLA
Attending Pathologist, City of Hope

JASON CHANG
Attending Pathologist, MSKCC

PAOLO COTZIA
Attending Pathologist, New York University

SOUNAK GUPTA
Genitourinary Pathology Fellowship, MSKCC

CHAD VANDERBILT
Attending Pathologist, MSKCC

VITOR WERNECK SILVA
Sabbatical Leave


